Literature DB >> 30105413

Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Asmin Andries1, Kristien Daenen2,3, François Jouret4,5, Bert Bammens2,3, Djalila Mekahli6,7, Ann Van Schepdael8.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in PKD1 or PKD2 genes, is the most common hereditary renal disease. Renal manifestations of ADPKD are gradual cyst development and kidney enlargement ultimately leading to end-stage renal disease. ADPKD also causes extrarenal manifestations, including endothelial dysfunction and hypertension. Both of these complications are linked with reduced nitric oxide levels related to excessive oxidative stress (OS). OS, defined as disturbances in the prooxidant/antioxidant balance, is harmful to cells due to the excessive generation of highly reactive oxygen and nitrogen free radicals. Next to endothelial dysfunction and hypertension, there is cumulative evidence that OS occurs in the early stages of ADPKD. In the current review, we aim to summarize the cardiovascular complications and the relevance of OS in ADPKD and, more specifically, in the early stages of the disease. First, we will briefly introduce the link between ADPKD and the early cardiovascular complications including hypertension. Secondly, we will describe the potential role of OS in the early stages of ADPKD and its possible importance beyond the chronic kidney disease (CKD) effect. Finally, we will discuss some pharmacological agents capable of reducing reactive oxygen species and OS, which might represent potential treatment targets for ADPKD.

Entities:  

Keywords:  ADPKD; Cardiovascular complications; Children; Early stages; Endothelial dysfunction; Oxidative stress; Young adults

Mesh:

Year:  2018        PMID: 30105413     DOI: 10.1007/s00467-018-4004-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  110 in total

1.  Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure.

Authors:  Leonard P Van der Zwan; Peter G Scheffer; Jacqueline M Dekker; Coen D A Stehouwer; Robert J Heine; Tom Teerlink
Journal:  Hypertension       Date:  2010-04-12       Impact factor: 10.190

2.  PKD1 interacts with PKD2 through a probable coiled-coil domain.

Authors:  F Qian; F J Germino; Y Cai; X Zhang; S Somlo; G G Germino
Journal:  Nat Genet       Date:  1997-06       Impact factor: 38.330

Review 3.  Hypertension in autosomal dominant polycystic kidney disease.

Authors:  Arlene B Chapman; Konrad Stepniakowski; Frederic Rahbari-Oskoui
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 4.  Reactive oxygen species and vascular biology: implications in human hypertension.

Authors:  Rhian M Touyz; Ana M Briones
Journal:  Hypertens Res       Date:  2010-10-28       Impact factor: 3.872

5.  Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study.

Authors:  Christine Patch; Judith Charlton; Paul J Roderick; Martin C Gulliford
Journal:  Am J Kidney Dis       Date:  2011-04-02       Impact factor: 8.860

6.  Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease.

Authors:  Huseyin Oflaz; Sabahat Alisir; Banu Buyukaydin; Orhan Kocaman; Faruk Turgut; Sule Namli; Burak Pamukcu; Aytac Oncul; Tevfik Ecder
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

7.  Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease.

Authors:  M Zeier; S Geberth; K G Schmidt; A Mandelbaum; E Ritz
Journal:  J Am Soc Nephrol       Date:  1993-02       Impact factor: 10.121

8.  The spectrum of autosomal dominant polycystic kidney disease in children.

Authors:  G M Fick; I T Duley; A M Johnson; J D Strain; M L Manco-Johnson; P A Gabow
Journal:  J Am Soc Nephrol       Date:  1994-03       Impact factor: 10.121

9.  Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability.

Authors:  Ming-Sheng Zhou; Ivonne Hernandez Schuman; Edgar A Jaimes; Leopoldo Raij
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-07

Review 10.  Endothelial function and oxidative stress in cardiovascular diseases.

Authors:  Yukihito Higashi; Kensuke Noma; Masao Yoshizumi; Yasuki Kihara
Journal:  Circ J       Date:  2009-02-04       Impact factor: 2.993

View more
  9 in total

Review 1.  Filtering through the role of NRF2 in kidney disease.

Authors:  Cody J Schmidlin; Matthew B Dodson; Donna D Zhang
Journal:  Arch Pharm Res       Date:  2019-08-01       Impact factor: 4.946

Review 2.  Oxidative stress in chronic kidney disease.

Authors:  Kristien Daenen; Asmin Andries; Djalila Mekahli; Ann Van Schepdael; François Jouret; Bert Bammens
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

3.  A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease.

Authors:  Mehmet Kanbay; Aslihan Yerlikaya; Alan A Sag; Alberto Ortiz; Masanari Kuwabara; Adrian Covic; Andrzej Wiecek; Peter Stenvinkel; Baris Afsar
Journal:  Clin Kidney J       Date:  2019-09-18

4.  Overexpression of DJ-1 alleviates autosomal dominant polycystic kidney disease by regulating cell proliferation, apoptosis, and mitochondrial metabolism in vitro and in vivo.

Authors:  Zhongxin Li; Jingjing Zhou; Yan Li; Fan Yang; Xiaoying Lian; Wenhu Liu
Journal:  Ann Transl Med       Date:  2020-09

5.  Cyst Reduction by Melatonin in a Novel Drosophila Model of Polycystic Kidney Disease.

Authors:  Cassandra Millet-Boureima; Roman Rozencwaig; Felix Polyak; Chiara Gamberi
Journal:  Molecules       Date:  2020-11-23       Impact factor: 4.411

Review 6.  Insights Into the Molecular Mechanisms of Polycystic Kidney Diseases.

Authors:  Valeriia Y Vasileva; Regina F Sultanova; Anastasia V Sudarikova; Daria V Ilatovskaya
Journal:  Front Physiol       Date:  2021-09-08       Impact factor: 4.566

Review 7.  Predictors of progression in autosomal dominant and autosomal recessive polycystic kidney disease.

Authors:  Eric G Benz; Erum A Hartung
Journal:  Pediatr Nephrol       Date:  2021-01-21       Impact factor: 3.651

8.  Obacunone Retards Renal Cyst Development in Autosomal Dominant Polycystic Kidney Disease by Activating NRF2.

Authors:  Zhiwei Qiu; Jinzhao He; Guangying Shao; Jiaqi Hu; Xiaowei Li; Hong Zhou; Min Li; Baoxue Yang
Journal:  Antioxidants (Basel)       Date:  2021-12-24

9.  Rapidly Progressing to ESRD in an Individual with Coexisting ADPKD and Masked Klinefelter and Gitelman Syndromes.

Authors:  Ramón Peces; Carlos Peces; Rocío Mena; Emilio Cuesta; Fe Amalia García-Santiago; Marta Ossorio; Sara Afonso; Pablo Lapunzina; Julián Nevado
Journal:  Genes (Basel)       Date:  2022-02-23       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.